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A scoring system to detect fixed 
airflow limitation in smokers from 
simple easy-to-use parameters
Esther Román-Conejos1, Antonio Palazón-Bru2, David Manuel Folgado-de la Rosa2, 
Manuel Sánchez-Molla3, María Mercedes Rizo-Baeza4, Vicente Francisco Gil-Guillén2 & 
Ernesto Cortés-Castell5
No validated screening method currently exists for Chronic Obstructive Pulmonary Disease (COPD) in 
smokers. Therefore, we constructed a predictive model with simple parameters that can be applied for 
COPD screening to detect fixed airflow limitation. This observational cross-sectional study included 
a random sample of 222 smokers with no previous diagnosis of COPD undertaken in a Spanish region 
in 2014–2016. The main variable was fixed airflow limitation by spirometry. The secondary variables 
(COPD factors) were: age, gender, smoking (pack-years and Fagerström test), body mass index, 
educational level, respiratory symptoms and exacerbations. A points system was developed to predict 
fixed airflow limitation based on secondary variables. The model was validated internally through 
bootstrapping, determining discrimination and calibration. The system was then integrated into a 
mobile application for Android. Fifty-seven patients (25.7%) presented fixed airflow limitation. The 
points system included as predictors: age, pack-years, Fagerström test and presence of respiratory 
symptoms. Internal validation of the system was very satisfactory, both in discrimination and 
calibration. In conclusion, a points system has been constructed to predict fixed airflow limitation in 
smokers with no previous COPD. This system can be integrated as a screening tool, though it should be 
externally validated in other geographical regions.
Chronic obstructive pulmonary disease (COPD) is a major public health problem, making it the fourth leading 
cause of death worldwide1. Despite its associated morbidity and mortality and the considerable expenditure of 
resources generated by COPD, it is underdiagnosed worldwide2–4.
The main risk factor for COPD is smoking5. Other factors include age, male gender and respiratory symp-
toms6. COPD has also been associated with certain chronic comorbidities such as hypertension, cardiovascular 
problems, and diabetes7,8.
The most commonly accepted method to confirm COPD is forced spirometry, which is considered posi-
tive with a post-bronchodilator forced expiratory volume in the first second (FEV1)/forced vital capacity (FVC) 
ratio < 0.7. This is a simple, reproducible technique with low individual cost9,10. Although it is indicated in 
patients with respiratory symptoms, in normal clinical practice it is underutilized11, thereby explaining part of 
the underdiagnosis. Thus, forced spirometry does not appear to be a good screening technique that can be applied 
in all smokers regardless of their symptoms because, in most cases, these symptoms become evident when the 
disease is already established or when they already affect quality of life, which is associated with a greater severity 
of the disease12,13.
As there is no established early screening program, alternatives for the early detection of COPD have been 
proposed. These may prove useful prior to confirmation by spirometry to reduce the high prevalence of under-
diagnosis. There are only three models to predict COPD in patients with a high risk of developing the disorder 
but with no prior history of lung disease (Table 1). Although these models are easy to use in general clinical 
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practice as they employ variables that are easy to obtain and the risk of COPD is calculated with a scoring system, 
they nevertheless suffer from important limitations concerning their development (estimation) and their internal 
validation. Concerning the former, two of the models present overfitting (events-per-variable < 10), none of the 
three analysed the functional form of the continuous predictors and the treatment of missing data is not given; 
in addition to which only one model selected the predictors based on the overall goodness of fit of the model. 
Concerning the validation, this was not done by bootstrapping in any of the models and the calibration was not 
done with smooth curves to estimate the observed probability of COPD14–16. Accordingly, no real model to pre-
dict COPD is available for use as a screening tool developed with the best and recommended statistical technique.
As a response to the need to implement a screening method that can differentiate smokers with a higher risk of 
fixed airflow limitation prior to onset of established symptoms, the objective of this study was the elaboration and 
internal validation (bootstrapping) of a prediction model for fixed airflow limitation, using the recommended 
statistical methodology14–16, with simple parameters that can be implemented in routine clinical practice in a 
systematic way, without incurring an increase in care time. In addition, to facilitate the implementation of this 
model, it will be integrated into a mobile phone application in the Android operating system (COPD predictor in 
Google Play), which could be used even by patients. With all this, we will have a screening tool that, provided it is 
externally validated in other populations, could be integrated into the protocols and clinical guidelines for COPD, 
prior to the definitive diagnosis by forced spirometry and respiratory symptoms. Whilst COPD screening is not 
currently recommended in smokers, this is because the techniques to do so are time consuming and expensive. 
Therefore, in this study we present an alternative that overcomes these limitations and leaves spirometry for con-
firmation in high-risk cases.
Method
Study Population. Smokers aged 40–75 years with no previous diagnosis of COPD whose primary health 
care is delivered at the Raval Health Centre in Elche (Alicante). This centre covers a population of 20,284 adults 
and is a primary care centre of the Spanish Public Health System which provides universal and free coverage.
Study design and participants. This cross-sectional observational study was carried out during 2014–
2016 with the objective of determining the underdiagnosis of COPD resulting from the underuse of forced 
spirometry and with this to construct a predictive model. We consulted the outpatient database of this centre and 
excluded those patients who did not meet the following inclusion criteria: smokers, age 40–75 years, and with no 
active diagnosis of COPD in their medical record. From the list obtained in this consultation, a group of patients 
was selected by random sampling (random number table) and contacted by telephone, asking them over the 
phone for their informed consent to participate in the study. The patients who agreed to participate were asked to 
perform forced spirometry, fill out questionnaires on COPD risk factors, and sign the written informed consent. 
Just under 10% of those selected refused to participate (generally due to incompatible work schedules, n = 24, 
9.8%). These patients were passed over and the next person in the random table was selected.
Variables and measurements. The primary variable was fixed airflow limitation performed with a val-
idated Datospir 110 A spirometer, according to the regulations of the main Spanish medical societies and the 
criteria established in the GOLD guide (post-bronchodilator FEV1/FVC ratio < 0.7)12,17.
Secondary variables were collected according to the risk factors associated with the diagnosis of COPD: older 
age, male gender, number of cigarettes smoked and for how long, low body mass index (BMI), low educational 
level, presence of respiratory symptoms and exacerbations during the last year4,8,18–20. In the interview details 
were obtained about: gender; age; educational level (0 = primary, 1 = secondary-intermediate degree, 2 = higher 
studies-University); smoking history in pack-years, calculated as the number of cigarettes smoked per day 
Reference Population Variables Clinical use EPV ≥ 10
Continuous 
variables Missing data
Model building 
strategy Discrimination
López-Varela 
et al.38 COPD risk
Gender, age, pack-years, 
dyspnoea, chronic phlegm 
and cough, and previous 
spirometry
Scoring system Yes Categorization Not mentioned Used all their  co-variables
AUC, sensitivity 
and specificity, no 
bootstrapping
Llordés  
et al.39 Smokers
Age, gender, BMI, pack-
years, profession of risk, 
expectoration, dyspnoea, 
cold complications, dyspnoea 
treatment and cardiovascular 
disease
Scoring system No Categorization Not mentioned
Selection based 
on bivariate 
analysis
AUC, sensitivity 
and specificity, no 
bootstrapping
Price  
et al.40,41 COPD risk
Age, BMI, pack-years, cough 
due to the weather, phlegm, 
breathlessness and allergies
Scoring system No Categorization Not mentioned
Stepwise selection 
based on bivariate 
analyses, factor 
analysis and AIC
AUC, sensitivity 
and specificity, no 
bootstrapping
Table 1. Analysis of the published studies that developed a predictive model to diagnose chronic obstructive 
pulmonary disease in risk populations (screening). Abbreviations: A.I.C., Akaike’s Information Criterion; 
A.U.C., area under the receiver operating characteristic curve; B.M.I., body mass index; C.O.P.D., chronic 
obstructive pulmonary disease; E.P.V., events-per-variable; C.O.P.D. risk is defined as being current or former 
smoker. Note that it is entirely possible that the mentioned limitations could be overcome by a subsequent 
successful external validation.
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multiplied by the number of years smoking divided by 20; Fagerström test, considering three levels of depend-
ence: mild (0–3 points), moderate (4–6 points) and severe (7–10 points)21; presence of symptoms or respiratory 
problems (aphonia, cough, catarrh, bronchitis, etc.) requiring medical consultation during the last year and level 
of exacerbation, described as a sustained deterioration in the patient’s baseline clinical condition, beyond the 
usual daily variability, which appears acutely, and is accompanied by increased dyspnoea and expectoration and a 
change in the appearance of sputum, or any combination of these three symptoms, requiring a therapeutic change 
and classified as mild (no episodes of bronchitis in the last year), moderate (episodes treated by primary care 
physician) and severe (treated in the emergency area and/or hospitalisation)22.
Sample size calculation. Since the objective of this study was to construct a predictive model of a binary 
event through a binary logistic regression model, the sample size had to verify that the ratio between the number 
of events and the number of predictors of the model was greater than or equal to 1023.
Statistical analysis. Qualitative variables were described using absolute and relative frequencies, whilst 
quantitative variables were expressed through means and standard deviations. Our variables had no missing 
data. Associations between the primary variable and the secondary variables were assessed using the X2 test and 
the t-test. A logistic regression model was constructed with a maximum number of five predictors (57 patients 
with fixed airflow limitation). Taking into account that we had a total of 8 predictors [considering educational 
level and the Fagerström test as linear predictors, as they did not show a quadratic trend (Wald test)], we checked 
all possible combinations of 1 to 5 predictors, selecting the one with the highest discriminating capacity, that is, 
the one that gave a maximum area under the receiver operating characteristic curve (AUC). Thus, the AUC was 
calculated in a total of 218 combinations. The optimum combination was adapted to a points system using the 
Framingham study methodology24 which, through a weighting of the model coefficients and a categorization of 
the predictors, associates a score to each variable and the sum of these scores gives an event probability. Once the 
points system was developed, it was internally validated through bootstrapping (1000 random samples), since this 
is the most recommended technique25. Discrimination was determined in each of the 1000 samples (the points 
system can differentiate fixed airflow limitation) and calibration (verifying that the prediction of the model cor-
responds to reality). Discrimination is addressed by calculating the AUC, whilst calibration is evaluated through 
the construction of smooth curves (linear splines) with the Hosmer-Lemeshow test, which is appropriate for the 
recommended level of calibration (moderate)15. All analyses were performed with a type I error of 5%, and for 
each relevant parameter its associated confidence interval (CI) was calculated. Statistical packages used were SPSS 
Statistics 24 and R 2.13.2.
Ethical approval. This project was approved by the Clinical Trials Ethics Committee of the Department of 
Health of the Generalitat Valenciana (General University Hospital of Elche, Alicante) at its meeting on 20 March 
2014, in accordance with the International Guidelines for Ethical Review of Epidemiological Studies and the 
recommendations of the Spanish Society of Epidemiology on the review of the ethical aspects of epidemiological 
research studies, respecting the rules set forth in Law 15/1999 on Personal Data Protection in research studies. 
The committee approved the age range of the patients in the study (40–75 years), as the highest prevalence of 
COPD occurs at these ages.
How This Fits In. The diagnosis of COPD is customarily made using forced spirometry and respiratory 
symptoms, but this does not appear to be a good screening technique that can be extended to all smokers. We 
elaborated and internally validated a prediction model for fixed airflow limitation with simple parameters that 
can be implemented in routine clinical practice in a systematic way. Care time would not be increased, since the 
model will be implemented in a mobile app for Android. With all this, we will have a screening tool that could be 
integrated, after external validation, in the protocols and clinical guidelines for COPD.
Results
Spirometry was performed in a total of 222 patients, of which 119 (53.6%) were men; 57 (25.7%) patients had 
fixed airflow limitation. Table 2 shows the values of the variables analysed; also shown are the results of the bivar-
iate analysis which revealed male gender, age, educational level, nicotine dependence (Fagerström), cigarette 
consumption, presence of respiratory symptoms and exacerbations to be significant risk factors (p < 0.05). The 
same table shows the coefficients of the multivariate model with the optimum combination to predict fixed air-
flow limitation. We highlight that this combination included: age, educational level, Fagerström test, pack-years 
smoked and presence of respiratory symptoms. Figure 1 illustrates the adaptation of the model to a points system 
(educational level was not present when we adapted the model to a scoring system). Figure 2 depicts the logistic 
tendency for the probability of fixed airflow limitation as the overall score increases.
The internal validation of the points system using the bootstrap technique was very satisfactory. First, in Fig. 3 
we can see that the discrimination is adequate, as the central value of the AUC distribution is 0.80. Subsequently, 
Fig. 4 shows that the observed versus expected probabilities. Note that most of the scores had small errors, except 
when the patient had 6 points (15.36%), but these patients had a proportion of 10.8% in the sample and overall 
this was appropriate (Hosmer-Lemeshow test: p = 0.492). Consequently, the points system has been internally 
validated with satisfactory calibration and discrimination.
Discussion
Summary. This study developed a simple prediction tool to assess fixed airflow limitation in smokers with no 
previous diagnosis of COPD. The model is simple to use because the variables are easy to measure, risk is assessed 
by a points system and its implementation in a mobile application makes calculations even easier. The model has 
been internally validated in our setting through the most recommended statistical methods. Underdiagnosis of 
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Variable
Total n = 222 
n(%)/x ± s
Fixed airflow limitation 
n = 57(25.7%) n(%)/x ± s p-value
Adj. OR (95% 
CI) p-value
Male gender 119(53.6) 37(31.1) 0.047 N/M N/M
Age (years) 56.8 ± 10.4 63.8 ± 9.2 <0.001 1.08(1.03–1.14) 0.001
Educational level*:
   Primary
   Secondary
   University
78(35.1)
87(39.2)
57(25.7)
29(37.2)
19(21.8)
9(15.8)
0.011 1.03(0.61–1.75) 0.902
Fagerström test (dependence)*:
   Low
   Moderate
   High
90(40.5)
113(50.9)
19(8.6)
12(13.3)
33(29.2)
12(63.2)
<0.001 2.06(1.07–3.99) 0.032
   Smoking pack-years 28.8 ± 13.4 38.6 ± 11.8 <0.001 1.04(1.01–1.07) 0.021
   Respiratory symptoms 88(39.6) 41(46.6) <0.001 4.36(2.01–9.46) <0.001
Exacerbation*:
   Mild
   Moderate
   Severe
147(66.2)
67(30.2)
8(3.6)
22(15.0)
28(41.8)
7(87.5)
<0.001 N/M N/M
   BMI (kg/m2) 26.6 ± 4.8 27.1 ± 5.8 0.387 N/M N/M
Table 2. Predictive model for fixed airflow limitation in smokers with no previous diagnosis of chronic 
obstructive pulmonary disease in primary health care. Abbreviations: Adj. O.R., adjusted odds ratio; B.M.I., 
body mass index; C.I., confidence interval; n(%), absolute frequency (relative frequency) N/M, not in the model; 
x ± s, mean ± standard deviation. *Analysed in the multivariate model as a quantitative variable. Goodness-of-
fit of the multivariate model (likelihood ratio test): χ2 = 11.5, p < 0.001.
Figure 1. Scoring system to predict the diagnosis of fixed airflow limitation in smokers. The box on the left 
shows the overall scores with their associated risk of fixed airflow limitation.
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COPD in our population was 25.7% (fixed airflow limitation), with the following associated risk factors: male 
gender, older age, lower educational level, higher level of nicotine dependence (Fagerström), higher cigarette 
consumption, presence of respiratory symptoms and high level of exacerbations.
Strengths and limitations. The main strength of our study is the development and internal validation of a 
prediction model for COPD screening in patients prior to diagnostic confirmation by spirometry and respiratory 
symptoms. Although others have developed a prediction model, their models have several limitations for use in 
clinical practice (Table 1). We also highlight the statistical methodology used since we chose the combination of 
explanatory variables of the multivariate model with the highest discriminating capacity. Additionally, we used 
the most recommended techniques for the validation of a predictive model of a binary event14–16,25.
Figure 2. Predicted probability of fixed airflow limitation using our scoring system.
Figure 3. Area under the Receiver Operating Characteristic curve distribution for the validation of our scoring 
system using the bootstrap method. Abbreviations: AUC, area under the Receiver Operating Characteristic 
curve; CI, confidence interval.
Figure 4. Smooth calibration plots for the validation of our scoring system using the bootstrap method. The 
black line represents perfect calibration and the grey line indicates the results of our calibration. The error 
(observed-expected in %) in each score was (ordered from 0 to 10 points; in parentheses we indicate the 
proportion of patients with each score): 1.53 (7.7%), 0.34 (5.9%), −2.30 (18.9%), 1.08 (17.6%), 2.11 (14.0%), 
−6.05 (12.6%), −15.36 (10.8%), −1.53 (5.0%), 4.04 (5.4%), 3.95 (1.8%) and 2.48% (0.5%).
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Selection bias was minimized by randomly choosing the sample from among all smokers in the corresponding 
health area, with very low exclusion for not wanting to participate (about 10%). To minimize information bias, 
the tests were conducted by the principal investigator using validated questionnaires and instruments. To avoid 
possible confounding bias, we applied well-calibrated multivariate models with high discriminating capacity. Our 
main limitations were sample size (limiting the number of predictors) and lack of external validation (future line 
of research).
We could have used the lower limit criterion instead of setting the FEV1/FVC ratio threshold at 0.7. However, 
it has been seen in populations similar to ours that establishing the diagnosis of COPD with the lower limit 
could exclude a high number of patients with significant clinical impact and high consumption of healthcare 
resources26. We have also used a total of 8 explanatory variables to predict fixed airflow limitation, with a greater 
number of factors contributing to this problem. Nevertheless, the mathematical model had very good discrimi-
nation and good calibration.
Another point to take into account is that we did not have a sufficient sample size to externally validate the 
points system constructed. For this, a completely different sample should be available with at least 100 patients 
with fixed airflow limitation16. Our team is collecting a new sample for this purpose, and this type of study should 
also be carried out in other geographical areas to determine whether the predictive model is satisfactory for 
detecting fixed airflow limitation.
We would like to note that our points system is only applicable to patients without COPD who are current 
smokers and between the ages of 40 and 75 years. Patients with COPD who have no history of smoking have also 
been excluded, as they already have the disease and there is no point in screening. The exclusion of ex-smokers 
and elderly people could lead to an increase in the prevalence of fixed airflow limitation, and it should be verified 
in another study whether the model is applicable to these people, since the variables age, Fagerström test, and 
pack-years can be evaluated in these excluded patients. If similar results are obtained, the target population of our 
predictive model could be expanded.
Comparison with existing literature. The technique used to confirm the presence of COPD is still 
spirometry and respiratory symptoms12, but its use is limited and the effectiveness of extending it to the entire 
population is unknown11. Consequently, several authors have proposed the possibility of first using question-
naires aimed at detecting and classifying patients at high risk of COPD, in conjunction with the intermediate use 
of a pocket spirometer, and followed by confirmation with conventional spirometry in cases with low FEV1/FEV6 
figures11,27.
The older predictive models had major statistical limitations (Table 1). We used the recommended guidelines 
for developing a predictive model14–16 in order to develop a simple algorithm based on the data obtained in our 
study indicating the population at risk of COPD and that could go undetected. The tool can be used quickly in 
daily clinical practice by the primary care physician, or even with the development of a mobile application (app) 
that facilitates self-diagnosis by the patient (fixed airflow limitation), leading directly to the need for spirometry 
and assessment of respiratory symptoms to confirm the presence or absence of COPD and thus preventing the 
high levels of underdiagnosis. Consequently, this tool can be very useful, since the estimated worldwide preva-
lence of COPD is 1% in the general population and 8–10% in those aged over 40 years28, and between 2.1% to 
26.1% in Europe depending on country, method and population29.
Regarding risk factors associated with underdiagnosis, age and smoking are already recognized as the main 
risk factors for underdiagnosis3,12,20,30–34. Other studies refer to a higher risk of underdiagnosed COPD in cases 
of low educational level3, low socioeconomic status20, previous respiratory symptoms or high BMI (≥30 kg/m2)2, 
whilst others associate it with low BMI11. Underdiagnosis has also been associated with increased comorbidity, 
especially cardiovascular5,19,32,35,36. Therefore, we can confirm correspondence with the data found in our study.
Implications for research and/or practice. Our study provides a scoring system that is very easy to use 
in daily clinical practice that can facilitate the request for spirometry based on a calculated risk, making it a good 
model for COPD screening. For its use, once the result has been obtained in smokers who have attended the 
health care centre (opportunistic screening), the physician must evaluate the need for confirmation by spirome-
try, according to patient characteristics and cost-effectiveness. In addition, understanding their COPD risk may 
well encourage smokers who are already considering quitting to take the definitive step37. Because of its ease of 
use, this scoring system can be extended to the entire population through mobile applications (apps), enabling 
patients to easily understand their risk and thus serving as a coercive measure for quitting. In other words, the 
points obtained for age cannot be modified, but it is visible on the scale that quitting smoking can improve scores, 
both in nicotine dependence and in respiratory symptoms. It is also a tool that can save time in primary care 
consultations and in the use of spirometry by applying the technique only in cases with a high probability of fixed 
airflow limitation. Finally, this model (and those in Table 1) should be externally validated in other populations 
and its cost-effectiveness verified in order to be able to extend its use in primary care in other centres and clinical 
settings. It also raises issues that open lines of investigation in the action against smoking and target population.
Data Availability
The data that support the findings of this study are available from Esther Román-Conejos but restrictions apply to 
the availability of these data, which were used under license for the current study, and so are not publicly available. 
Data are however available from the authors upon reasonable request and with permission of the Clinical Trials 
Ethics Committee of the Department of Health of the Generalitat Valenciana (General University Hospital of 
Elche, Alicante).
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